{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:53:16Z","timestamp":1765475596933,"version":"3.48.0"},"reference-count":20,"publisher":"Innovative Healthcare Institute","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are often associated with inflammatory toxicities known as immune-related adverse events (irAEs). Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is an atypical inflammatory arthritis. Herein, we report a case of RS3PE in a patient with metastatic prostate cancer who was receiving a combination of second-generation hormonal therapies plus ipilimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>A 59-year-old man with metastatic prostate cancer developed sudden onset of pain and swelling of the right hand after 15 weeks of treatment with second-generation hormonal therapies plus three cycles of ipilimumab. Symptoms alternated to the left hand. Physical examination showed tender, pitting edema of the left hand with tenderness on the right second through fifth metacarpal phalangeal joints, leading to the diagnosis of RS3PE. Ipilimumab was withheld, and the RS3PE self-resolved; however, 1 month later, the patient had another flare of RS3PE. A bone scan showed active inflammation on bilateral wrists and hands. Methotrexate was initiated, and his symptoms resolved over a few days. Methotrexate was discontinued 2 months later, and RS3PE has been in complete remission. His prostate cancer progressed, and radium-223 treatment was initiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To the best of our knowledge, this is the first reported case of RS3PE after the combined second-generation hormonal therapy plus ipilimumab. Both rheumatologists and oncologists should be aware that RS3PE can develop as an irAE. Understanding the mechanism of ICI therapy\u2013associated RS3PE is critical to identify predictive biomarkers and develop optimal therapeutic strategies that do not sacrifice antitumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-20-2","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T16:54:44Z","timestamp":1596732884000},"page":"128-132","source":"Crossref","is-referenced-by-count":5,"title":["RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer"],"prefix":"10.36401","volume":"3","author":[{"given":"Sang T.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, Section of Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"William A.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22027","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"2021072121213118600_i2590-017X-3-3-128-b01","doi-asserted-by":"crossref","unstructured":"Calabrese\n              LH,\n            \n            \n              Calabrese\n              C,\n            \n            \n              Cappelli\n              LC.\n            \n          \n          Rheumatic immune-related adverse events from cancer immunotherapy.\n\t\t\t\t\tNat Rev Rheumatol.\n\t\t\t\t\t2018;\n\t\t\t\t\t14:\n\t\t\t\t\t569\u2013\n\t\t\t\t\t579.","DOI":"10.1038\/s41584-018-0074-9"},{"key":"2021072121213118600_i2590-017X-3-3-128-b02","unstructured":"Olivieri\n              I,\n            \n            \n              Salvarani\n              C,\n            \n            \n              Cantini\n              F.\n            \n          \n          RS3PE syndrome: an overview.\n\t\t\t\t\tClin Exp Rheumatol.\n\t\t\t\t\t2000;\n\t\t\t\t\t18:\n\t\t\t\t\tS53\u2013\n\t\t\t\t\tS55."},{"key":"2021072121213118600_i2590-017X-3-3-128-b03","doi-asserted-by":"crossref","unstructured":"Boutros\n              C,\n            \n            \n              Tarhini\n              A,\n            \n            \n              Routier\n              E,\n            \n            et al.\n\t\t\t\t\t\n          Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.\n\t\t\t\t\tNat Rev Clin Oncol.\n\t\t\t\t\t2016;\n\t\t\t\t\t13:\n\t\t\t\t\t473\u2013\n\t\t\t\t\t486.","DOI":"10.1038\/nrclinonc.2016.58"},{"key":"2021072121213118600_i2590-017X-3-3-128-b04","doi-asserted-by":"crossref","unstructured":"Buder-Bakhaya\n              K,\n            \n            \n              Benesova\n              K,\n            \n            \n              Schulz\n              C,\n            \n            et al.\n\t\t\t\t\t\n          Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies.\n\t\t\t\t\tCancer Immunol Immunother.\n\t\t\t\t\t2018;\n\t\t\t\t\t67:\n\t\t\t\t\t175\u2013\n\t\t\t\t\t182.","DOI":"10.1007\/s00262-017-2069-9"},{"key":"2021072121213118600_i2590-017X-3-3-128-b05","doi-asserted-by":"crossref","unstructured":"McCarty\n              DJ,\n            \n            \n              O'Duffy\n              JD,\n            \n            \n              Pearson\n              L,\n            \n            \n              Hunter\n              JB.\n            \n          \n          Remitting seronegative symmetrical synovitis with pitting edema: RS3PE syndrome.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t1985;\n\t\t\t\t\t254:\n\t\t\t\t\t2763\u2013\n\t\t\t\t\t2767.","DOI":"10.1001\/jama.254.19.2763"},{"key":"2021072121213118600_i2590-017X-3-3-128-b06","unstructured":"Torres\n              A,\n            \n            \n              Cuende\n              E,\n            \n            \n              De Pablos\n              M,\n            \n            \n              Lezaun\n              MJ,\n            \n            \n              Michaus\n              L,\n            \n            \n              Vesga\n              JC.\n            \n          \n          Remitting seronegative symmetrical synovitis with pitting edema associated with subcutaneous Streptobacillus moniliformis abscess.\n\t\t\t\t\tJ Rheumatol.\n\t\t\t\t\t2001;\n\t\t\t\t\t28:\n\t\t\t\t\t1696\u2013\n\t\t\t\t\t1698."},{"key":"2021072121213118600_i2590-017X-3-3-128-b07","unstructured":"Perandones\n              CE,\n            \n            \n              Colmegna\n              I,\n            \n            \n              Arana\n              RM.\n            \n          \n          Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema.\n\t\t\t\t\tJ Rheumatol.\n\t\t\t\t\t2005;\n\t\t\t\t\t32:\n\t\t\t\t\t389\u2013\n\t\t\t\t\t390."},{"key":"2021072121213118600_i2590-017X-3-3-128-b08","unstructured":"Karmacharya\n              P,\n            \n            \n              Donato\n              AA,\n            \n            \n              Aryal\n              MR,\n            \n            et al.\n\t\t\t\t\t\n          RS3PE revisited: a systematic review and meta-analysis of 331 cases.\n\t\t\t\t\tClin Exp Rheumatol.\n\t\t\t\t\t2016;\n\t\t\t\t\t34:\n\t\t\t\t\t404\u2013\n\t\t\t\t\t415."},{"key":"2021072121213118600_i2590-017X-3-3-128-b09","doi-asserted-by":"crossref","unstructured":"Arima\n              K,\n            \n            \n              Origuchi\n              T,\n            \n            \n              Tamai\n              M,\n            \n            et al.\n\t\t\t\t\t\n          RS3PE syndrome presenting as vascular endothelial growth factor associated disorder.\n\t\t\t\t\tAnn Rheum Dis.\n\t\t\t\t\t2005;\n\t\t\t\t\t64:\n\t\t\t\t\t1653\u2013\n\t\t\t\t\t1655.","DOI":"10.1136\/ard.2004.032995"},{"key":"2021072121213118600_i2590-017X-3-3-128-b10","doi-asserted-by":"crossref","unstructured":"Origuchi\n              T,\n            \n            \n              Arima\n              K,\n            \n            \n              Kawashiri\n              SY,\n            \n            et al.\n\t\t\t\t\t\n          High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome.\n\t\t\t\t\tMod Rheumatol.\n\t\t\t\t\t2012;\n\t\t\t\t\t22:\n\t\t\t\t\t584\u2013\n\t\t\t\t\t588.","DOI":"10.3109\/s10165-011-0556-y"},{"key":"2021072121213118600_i2590-017X-3-3-128-b11","unstructured":"Oide\n              T,\n            \n            \n              Ohara\n              S,\n            \n            \n              Oguchi\n              K,\n            \n            et al.\n\t\t\t\t\t\n          Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients.\n\t\t\t\t\tClin Exp Rheumatol.\n\t\t\t\t\t2004;\n\t\t\t\t\t22:\n\t\t\t\t\t91\u2013\n\t\t\t\t\t98."},{"key":"2021072121213118600_i2590-017X-3-3-128-b12","doi-asserted-by":"crossref","unstructured":"Nagashima\n              M,\n            \n            \n              Wauke\n              K,\n            \n            \n              Hirano\n              D,\n            \n            et al.\n\t\t\t\t\t\n          Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis.\n\t\t\t\t\tRheumatology (Oxford).\n\t\t\t\t\t2000;\n\t\t\t\t\t39:\n\t\t\t\t\t1255\u2013\n\t\t\t\t\t1262.","DOI":"10.1093\/rheumatology\/39.11.1255"},{"key":"2021072121213118600_i2590-017X-3-3-128-b13","doi-asserted-by":"crossref","unstructured":"Gauci\n              ML,\n            \n            \n              Baroudjian\n              B,\n            \n            \n              Laly\n              P,\n            \n            et al.\n\t\t\t\t\t\n          Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.\n\t\t\t\t\tSemin Arthritis Rheum.\n\t\t\t\t\t2017;\n\t\t\t\t\t47:\n\t\t\t\t\t281\u2013\n\t\t\t\t\t287.","DOI":"10.1016\/j.semarthrit.2017.03.003"},{"key":"2021072121213118600_i2590-017X-3-3-128-b14","doi-asserted-by":"crossref","unstructured":"Ngo\n              L,\n            \n            \n              Miller\n              E,\n            \n            \n              Valen\n              P,\n            \n            \n              Gertner\n              E.\n            \n          \n          Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report.\n\t\t\t\t\tJ Med Case Rep.\n\t\t\t\t\t2018;\n\t\t\t\t\t12:\n\t\t\t\t\t48.","DOI":"10.1186\/s13256-018-1579-1"},{"key":"2021072121213118600_i2590-017X-3-3-128-b15","doi-asserted-by":"crossref","unstructured":"Filetti\n              M,\n            \n            \n              Anselmi\n              E,\n            \n            \n              Macrini\n              S,\n            \n            et al.\n\t\t\t\t\t\n          Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.\n\t\t\t\t\tSemin Arthritis Rheum.\n\t\t\t\t\t2018;\n\t\t\t\t\t48:\n\t\t\t\t\te17\u2013\n\t\t\t\t\te20.","DOI":"10.1016\/j.semarthrit.2017.12.013"},{"key":"2021072121213118600_i2590-017X-3-3-128-b16","doi-asserted-by":"crossref","unstructured":"Wada\n              N,\n            \n            \n              Uchi\n              H,\n            \n            \n              Furue\n              M.\n            \n          \n          Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.\n\t\t\t\t\tJ Dermatol.\n\t\t\t\t\t2017;\n\t\t\t\t\t44:\n\t\t\t\t\te196\u2013\n\t\t\t\t\te197.","DOI":"10.1111\/1346-8138.13840"},{"key":"2021072121213118600_i2590-017X-3-3-128-b17","doi-asserted-by":"crossref","unstructured":"Amini-Adle\n              M,\n            \n            \n              Piperno\n              M,\n            \n            \n              Tordo\n              J,\n            \n            et al.\n\t\t\t\t\t\n          Remitting seronegative symmetric synovitis with pitting edema associated with partial melanoma response under anti-CTLA-4 and anti-programmed death 1 combination treatment.\n\t\t\t\t\tArthritis Rheumatol.\n\t\t\t\t\t2018;\n\t\t\t\t\t70:\n\t\t\t\t\t1358.","DOI":"10.1002\/art.40506"},{"key":"2021072121213118600_i2590-017X-3-3-128-b18","doi-asserted-by":"crossref","unstructured":"Redman\n              JM,\n            \n            \n              Rhea\n              LP,\n            \n            \n              Cordes\n              L,\n            \n            et al.\n\t\t\t\t\t\n          A case of anti-PD-L1-associated remitting seronegative symmetric synovitis with pitting edema.\n\t\t\t\t\tClin Genitourin Cancer.\n\t\t\t\t\t2019;\n\t\t\t\t\t17:\n\t\t\t\t\te549\u2013\n\t\t\t\t\te552.","DOI":"10.1016\/j.clgc.2019.02.005"},{"key":"2021072121213118600_i2590-017X-3-3-128-b19","doi-asserted-by":"crossref","unstructured":"Keenan\n              RT,\n            \n            \n              Hamalian\n              GM,\n            \n            \n              Pillinger\n              MH.\n            \n          \n          RS3PE presenting in a unilateral pattern: case report and review of the literature.\n\t\t\t\t\tSemin Arthritis Rheum.\n\t\t\t\t\t2009;\n\t\t\t\t\t38:\n\t\t\t\t\t428\u2013\n\t\t\t\t\t433.","DOI":"10.1016\/j.semarthrit.2008.03.008"},{"key":"2021072121213118600_i2590-017X-3-3-128-b20","doi-asserted-by":"crossref","unstructured":"Varshney\n              AN,\n            \n            \n              Kumar\n              N,\n            \n            \n              Tiwari\n              A,\n            \n            et al.\n\t\t\t\t\t\n          Unilateral RS3PE in a patient of seronegative rheumatoid arthritis.\n\t\t\t\t\tCase Rep Rheumatol.\n\t\t\t\t\t2013;\n\t\t\t\t\t2013:\n\t\t\t\t\t923797.","DOI":"10.1155\/2013\/923797"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/3\/3\/128\/2871018\/i2590-017x-3-3-128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/3\/3\/128\/2871018\/i2590-017x-3-3-128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:11Z","timestamp":1765475291000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/3\/3\/article-p128.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,5,14]]},"published-print":{"date-parts":[[2020,8,3]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-20-2","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"type":"electronic","value":"2590-017X"},{"type":"print","value":"2666-2345"}],"subject":[],"published":{"date-parts":[[2020,5,14]]}}}